Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - LIGAND PHARMACEUTICALS INClgnd_123117xexhibit321.htm
EX-10.60 - EXHIBIT 10.60 - LIGAND PHARMACEUTICALS INCindemnificationagreement-d.htm
EX-31.2 - EXHIBIT 31.2 - LIGAND PHARMACEUTICALS INClgnd_123117xexhibit312.htm
EX-31.1 - EXHIBIT 31.1 - LIGAND PHARMACEUTICALS INClgnd_123117xexhibit311.htm
EX-23.1 - EXHIBIT 23.1 - LIGAND PHARMACEUTICALS INClgnd_123117xexhibit231.htm
EX-21.1 - EXHIBIT 21.1 - LIGAND PHARMACEUTICALS INClgnd_123117xexhibit211.htm
EX-10.61 - EXHIBIT 10.61 - LIGAND PHARMACEUTICALS INCindemnificationagreement-o.htm
EX-10.7 - EXHIBIT 10.7 - LIGAND PHARMACEUTICALS INClgnd-rsugrantnoticeperform.htm
EX-10.6 - EXHIBIT 10.6 - LIGAND PHARMACEUTICALS INCformofrsugrantnoticeexhibi.htm
EX-4.1 - EXHIBIT 4.1 - LIGAND PHARMACEUTICALS INClgndexhibi41.htm
10-K - 10-K - LIGAND PHARMACEUTICALS INClgnd-20171231x10k.htm

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have issued our report dated February 26, 2016 (except for 2015 Restatement described in Note 1 in the previously filed 2015 financial statements, which is not presented herein and is as of November 14, 2016 and except for Condensed Statement of Operations table for Viking included in Note 2, which is as of March 1, 2018) with respect to the consolidated financial statements included in the Annual Report of Ligand Pharmaceuticals Incorporated on Form 10-K for the year ended December 31, 2015. We consent to the incorporation by reference of said report in the Registration Statements of Ligand Pharmaceuticals Incorporated on Forms S-3 (File No. 333-208919 and 333-191523) and on Forms S-8 (File No. 333-182547, File No. 333-160132 and File No. 333-131029).
 
/s/ GRANT THORNTON LLP
San Diego, California
March 1, 2018